Stefan Hirschberg, Fatemeh Ghazaani, Ghada Ben Amor, Markus Pydde, Alexander Nagel, Saveria Germani, Lara Monica, Anja Schlör, Hannes Bauer, Jane Hornung, Michael Voetz, Yamen Dwai, Benjamin Scheer, Frauke Ringel, Omar Kamal-Eddin, Christoph Harms, Jonas Füner, Lorenz Adrian, Axel Pruß, Kai Schulze-Forster, Katja Hanack, Julian Kamhieh-Milz
The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here, we describe a human cell line for cost-efficient and scalable production of immunogenic SARS-CoV-2 VLPs. The modular design of the VLP-production platform facilitates rapid adaptation to new variants. Methods: The N, M-, and E-protein genes were integrated into the genome of Expi293 cells (ExpiVLP_MEN)...
September 9, 2023: Vaccines